Clinical Trial Update: Ublituximab Followed by Response-driven Addition of Umbralisib for Treatment-naive Follicular or Marginal Zone Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating ublituximab followed by response-driven addition of umbralisib for treatment-naive follicular lymphoma or marginal zone lymphoma has co…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Follicular Lymphoma
• Marginal Zone Lymphoma

Drugs mentioned

• Ublituximab (ublituximab)
• umbralisib

Snippet

Sponsor: University of Colorado, Denver | Conditions: Marginal Zone Lymphoma, Follicular Lymphoma | Phase 2 | Status: COMPLETED | Results posted: 2023-11-09